Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 501, P. 157580 - 157580
Published: Nov. 10, 2024
Language: Английский
Acta Biomaterialia, Journal Year: 2024, Volume and Issue: 180, P. 1 - 17
Published: April 10, 2024
This analysis explores the principal regulatory concerns linked to nanomedicines and gene vaccines, including complexities involved perspectives on how navigate them. In realm of nanomedicines, ensuring safety nanomaterials is paramount due their unique characteristics potential interactions with biological systems. Regulatory bodies are actively formulating guidelines standards assess risks associated nanomedicine products, emphasizing need for standardized characterization techniques accurately gauge effectiveness. Regarding frameworks must be tailored address distinct challenges posed by genetic interventions, necessitating special considerations in efficacy evaluations, particularly concerning vector design, target specificity, long-term patient monitoring. Ethical such as autonomy, informed consent, privacy also demand careful attention, alongside intricate matter intellectual property rights, which balanced against imperative widespread access these life-saving treatments. Collaborative efforts among bodies, researchers, patent offices, private sector essential tackle effectively, international cooperation being especially crucial given global scope vaccine development. Striking right balance between safeguarding properties promoting public health vital fostering innovation equitable ground-breaking technologies, underscoring significance addressing hurdles fully harness benefits vaccines enhancing healthcare outcomes a scale. STATEMENT OF SIGNIFICANCE: Several biomaterials proposed development nanovaccines, from polymeric micelles, PLGA-/PEI-/PLL-nanoparticles, solid lipid nananoparticles, cationic lipoplexes, liposomes, hybrid materials, dendrimers, carbon nanotubes, hydrogels, quantum dots. Lipid nanoparticles (LNPs) have gained tremendous attention since US Food Drug Administration (FDA) approval Pfizer Moderna's COVID-19 raising awareness vaccines. review provides insights into current strategies issues, clinical trials. By navigating landscapes we can unlock full using range promising towards improving worldwide.
Language: Английский
Citations
36
Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)
Published: Aug. 9, 2024
The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI) tract cancers. role immune checkpoint inhibitors (ICIs), particularly programmed death protein 1 (PD-1) and PD ligand-1 antibodies, has become increasingly pivotal in treatment advanced perioperative GI Currently, anti-PD-1 plus chemotherapy is considered as first-line regimen unselected gastric/gastroesophageal junction adenocarcinoma (G/GEJC), mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC), esophageal (EC). In addition, encouraging performance claudin18.2-redirected chimeric antigen receptor T-cell (CAR-T) therapy later-line cancers brings new hope cell solid tumour treatment. Nevertheless, remains yet precise, researchers are dedicated to further maximising optimising efficacy. This review summarises important research, latest progress, future directions including EC, G/GEJC, CRC.
Language: Английский
Citations
21
ACS Nano, Journal Year: 2024, Volume and Issue: 18(29), P. 18801 - 18833
Published: July 9, 2024
Tumor vaccines, an important part of immunotherapy, prevent cancer or kill existing tumor cells by activating restoring the body's own immune system. Currently, various formulations vaccines have been developed, including cell membrane DNA mRNA polypeptide virus-vectored and tumor-in-situ vaccines. There are also multiple delivery systems for such as liposomes, vesicles, viruses, exosomes, emulsions. In addition, to decrease risk escape tolerance that may exist with a single vaccine, combination therapy radiotherapy, chemotherapy, checkpoint inhibitors, cytokines, CAR-T therapy, photoimmunotherapy is effective strategy. Given critical role in here, we look back history discuss antigens, adjuvants, formulations, systems, mechanisms, future directions
Language: Английский
Citations
10
Pharmacological Research, Journal Year: 2024, Volume and Issue: 206, P. 107308 - 107308
Published: July 15, 2024
Glioma is the most common intracranial malignant tumor, with severe difficulty in treatment and a low patient survival rate. Due to heterogeneity invasiveness of tumors, lack personalized clinical design, physiological barriers, it often difficult accurately distinguish gliomas, which dramatically affects subsequent diagnosis, imaging treatment, prognosis. Fortunately, nano-delivery systems have demonstrated unprecedented capabilities diagnosing treating gliomas recent years. They been modified surface efficiently traverse BBB/BBTB, target lesion sites, intelligently release therapeutic or contrast agents, thereby achieving precise treatment. In this review, we focus on systems. Firstly, provide an overview standard emerging diagnostic technologies for glioma practice. After induction analysis, summarizing delivery methods drug systems, design nanoparticles, their new advances Finally, discussed prospects potential challenges drug-delivery glioma.
Language: Английский
Citations
7
Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 378, P. 438 - 459
Published: Dec. 21, 2024
Cancer vaccines are promising therapeutic approaches to enhance specific T-cell immunity against most solid tumors. By stimulating anti-tumor immunity, clearing minimal residual disease, and minimizing adverse effects, these target tumor cells effective when combined with immune checkpoint blockade or other immunotherapies. However, the development of cell-based faces quality issues due poor immunogenicity, heterogeneity, a suppressive microenvironment, ineffective delivery methods. In contrast, extracellular vesicles (EVs), naturally released by cells, considered ideal drug carriers vaccine platforms. EVs offer highly organ-specific targeting, induce broader more responses, demonstrate superior tissue ability. The EV is crucial for advancing cancer immunotherapy. Compared vaccines, produced under Good Manufacturing Practices (GMP) advantages such as high safety, ease preservation transport, wide range sources. This review summarizes latest research findings on potential applications in this field. It also highlights novel neoantigens cancer.
Language: Английский
Citations
5
Nano-Micro Letters, Journal Year: 2024, Volume and Issue: 17(1)
Published: Sept. 30, 2024
Abstract Vaccinations are essential for preventing and treating disease, especially cancer nanovaccines, which have gained considerable interest recently their strong anti-tumor immune capabilities. Vaccines can prompt the system to generate antibodies activate various cells, leading a response against tumor tissues reducing negative effects recurrence risks of traditional chemotherapy surgery. To enhance flexibility targeting vaccines, nanovaccines utilize nanotechnology encapsulate or carry antigens at nanoscale level, enabling more controlled precise drug delivery responses. Cancer function by encapsulating tumor-specific tumor-associated within nanomaterials. The small size these nanomaterials allows T dendritic thereby eliciting potent response. In this paper, we focus on classification carriers roles different target clinically tested discussing strategies effectively inducing cytotoxic lymphocytes responses optimizing antigen presentation, while also looking ahead translational challenges moving from animal experiments clinical trials.
Language: Английский
Citations
4
MedComm, Journal Year: 2025, Volume and Issue: 6(1)
Published: Jan. 1, 2025
Abstract Messenger RNA (mRNA) therapeutics have garnered considerable attention due to their remarkable efficacy in the treatment of various diseases. The COVID‐19 mRNA vaccine and RSV been approved on market. Due inherent nuclease‐instability negative charge mRNA, delivery systems are developed protect from degradation facilitate its crossing cell membrane express functional proteins or peptides cytoplasm. However, deficiency transfection efficiency targeted biological distribution still major challenges for systems. In this review, we first described physiological barriers process then discussed design approach recent advances with an emphasis tissue/cell‐targeted abilities. Finally, pointed out existing future directions deep insights into efficient We believe that a high‐precision system can greatly improve therapeutic effects bio‐safety accelerate clinical transformations. This review may provide new direction serve as useful guide researchers who looking suitable system.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: Jan. 22, 2025
Despite the significant advancements in cancer research, innovative approaches are still needed to reduce tumor incidence, progression, and dissemination, as well for prolonging patient survival. Currently, development of vaccines is gaining attention a novel preventative therapeutic strategy. Although concept vaccination not new, limited number have received approval therapy. Heat shock protein (HSP)-based represents promising strategy that harnesses specific antigens activate immune responses. Exosomes (Exs) highly heterogeneous bilayer vesicles capable transporting various types molecules through extracellular space. Compared with conventional anticancer drugs, exosomes exhibit low toxicity good biocompatibility, they can stimulate system either directly or indirectly. Ex-based may elicit an antitumor response generates memory cells recognizing antigens, thereby inhibiting disease progression. This paper reviews potential applications HSPs prevention treatment solid tumors. Finally, we discuss advantages exosomal heat (HSP-Ex 1 ) vaccine future research directions aimed at optimizing protein-based immunotherapy strategies.
Language: Английский
Citations
0
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 17 - 35
Published: Feb. 3, 2025
Language: Английский
Citations
0
Essays in Biochemistry, Journal Year: 2025, Volume and Issue: 69(02)
Published: March 28, 2025
The emergence of immunotherapy has led to the clinical approval several related drugs. However, their efficacy against solid tumors remains limited. As hub immune activation, lymph nodes (LNs) play a critical role in tumor by initiating and amplifying responses. Nevertheless, intricate physiological structure barriers within LNs, combined with immunosuppressive microenvironment induced cells, significantly impede therapeutic immunotherapy. Engineered nanoparticles (NPs) have shown great potential overcoming these challenges facilitating targeted drug transport LNs directly or indirectly activating T cells. This review systematically examines structural features key factors influencing targeting efficiency NPs, current strategies for remodeling LNs. Additionally, it discusses future opportunities optimizing NPs enhance immunotherapy, addressing translation safety evaluation.
Language: Английский
Citations
0